Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2196.68% is 35% above its 5-year average of -3356.27%, near the high end of its 5-year range (-17500.86%–-1008.56%).
66.85% below its 12-month average of -1316.58%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2023 (2023-06-30): -1360.37%.
EBITDA MARGIN
-2196.68%
EBITDA MARGIN AVG TTM
-1316.58%
EBITDA MARGIN AVG 3Y
-1507.10%
EBITDA MARGIN AVG 5Y
-3356.27%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-66.85%
CURRENT VS 3Y AVG
-45.76%
CURRENT VS 5Y AVG
+34.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Niki BioSolutions, Inc.
Market Cap
$381940.00
EBITDA Margin
-2196.68%
TTM Avg
-1316.58%
3Y Avg
-1507.10%
5Y Avg
-3356.27%
Market Cap
$380715.00
EBITDA Margin
-47981.26%
TTM Avg
-69951.07%
3Y Avg
-52738.28%
5Y Avg
-42190.63%
Market Cap
$245237.00
EBITDA Margin
-994.74%
TTM Avg
-759.01%
3Y Avg
-558.46%
5Y Avg
-556.54%
Market Cap
$530421.00
EBITDA Margin
-8567.94%
TTM Avg
-8572.17%
3Y Avg
-8860.20%
5Y Avg
-7239.32%
Market Cap
$563178.00
EBITDA Margin
-18836.70%
TTM Avg
-9969.53%
3Y Avg
-5254.43%
5Y Avg
-4229.16%
Market Cap
$109735.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niki BioSolutions, Inc. (NIKI) | $381940.00 | -2196.68% | -1316.58% | -1507.10% | -3356.27% |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | -47981.26% | -69951.07% | -52738.28% | -42190.63% |
| XORTX Therapeutics Inc. (XRTX)vs › | $484571.00 | N/A | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $245237.00 | -994.74% | -759.01% | -558.46% | -556.54% |
| VivoSim Labs, Inc. (VIVS)vs › | $530421.00 | -8567.94% | -8572.17% | -8860.20% | -7239.32% |
| HCW Biologics Inc. (HCWB)vs › | $563178.00 | -18836.70% | -9969.53% | -5254.43% | -4229.16% |
| Silexion Therapeutics Ltd. (SLXN)vs › | $109735.00 | N/A | N/A | N/A | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $95097.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $678241.00 | N/A | N/A | N/A | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70876.00 | -24782.35% | -24782.35% | -17538.85% | -17538.85% |
Gross Margin
0.0%
EBITDA Margin
-2196.7%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2023-06-30 | -1360.37% |
| 2022-12-31 | -1097.46% |
| 2022-06-30 | -1491.92% |
| 2021-12-31 | -1008.56% |
| 2021-06-30 | -1395.01% |
| 2020-12-31 | -1878.35% |
| 2020-06-30 | -2318.05% |
| 2019-12-31 | -2942.03% |
| 2018-12-31 | -2570.08% |
| 2018-06-30 | -17500.86% |
